Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Osama Qaqi

Interventional Cardiology Plainfield, IL Medical Doctor

NPI 1508094210 CMS profile 159158

16519 S Route 59 Ste A, Plainfield, IL 60586

Open in the dashboard

General payments

$15,925

357 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$7,555 paid to institutions, not to them · program years 2021–2022

Through program year 2025, Osama Qaqi of Plainfield, IL is reported in the CMS Open Payments database as having received $15,925 across 357 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $7,555 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 70th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,963 61
2024 General $1,939 63
2023 General $4,703 66
2022 General $833 30
2021 General $1,506 38
2020 General $1,473 51
2019 General $3,509 48

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Osama Qaqi
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Osama Qaqi were reported at $1,963. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Osama Qaqi Interventional Cardiology median Middle half National median
2019 $3,509 $1,097 $329–$3,048 $163
2020 $1,473 $473 $161–$1,480 $114
2021 $1,506 $677 $233–$1,827 $132
2022 $833 $978 $333–$2,724 $149
2023 $4,703 $1,136 $382–$2,986 $160
2024 $1,939 $1,181 $395–$3,326 $164
2025 $1,963 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Inari Medical, Inc. $5,133 29 payments
  2. Medtronic Vascular, Inc. $1,799 10 payments
  3. Cardiovascular Systems Inc. $1,119 21 payments
  4. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $903 41 payments
  5. Tactile Systems Technology Inc $894 44 payments
  6. Abiomed $614 10 payments
  7. Bard Peripheral Vascular, Inc. $552 10 payments
  8. Abbott Laboratories $500 15 payments
  9. AstraZeneca Pharmaceuticals LP $441 20 payments
  10. Novartis Pharmaceuticals Corporation $371 17 payments
  11. Other $3,600 140 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,077 348 payments
  2. Travel and Lodging $4,848 9 payments
Products named General payments · program years 2019–2025
  1. CT THROMBECTOMY SYSTEM KIT $4,534 22 payments
  2. FLOWTRIEVER CATHETER, S $4,534 22 payments
  3. CoreValve Evolut $1,787 9 payments
  4. LifeVest $903 41 payments
  5. Flexitouch Plus $894 44 payments
  6. ClotTriever $599 7 payments
  7. FlowTriever $599 7 payments
  8. Impella $478 6 payments
  9. Entre Plus $434 25 payments
  10. Diamondback Peripheral $427 8 payments
  11. Other $6,224 241 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

979

Median for Interventional Cardiology: 2,236

Drug cost

$211,367

Median for Interventional Cardiology: $380,412

Branded share of claims

42.4%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 101 $93,248
Entresto Sacubitril/Valsartan Brand 49 $60,609
Xarelto Rivaroxaban Brand 21 $27,773
Jardiance Empagliflozin Brand 18 $18,881
Clopidogrel Clopidogrel Bisulfate Brand 133 $2,321
Atorvastatin Calcium Generic 141 $1,969
Ranolazine Er Ranolazine Brand 28 $1,888
Metoprolol Succinate Generic 62 $723
Carvedilol Generic 54 $698
Isosorbide Mononitrate Er Isosorbide Mononitrate Brand 42 $499

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 93 billing codes

Paid by Medicare

$157,308

Of which drugs: $1,029

Medicare patients

657

Average age 75

Services billed

1,859

330 women, 327 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 64%
Arthritis 56%
Diabetes 47%
Heart failure 44%
Chronic kidney disease 41%
Atrial fibrillation 37%
COPD 32%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 45 180 $833

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
WAINUA
  • AstraZeneca Pharmaceuticals LP $185
$185 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $144
$144 18 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $59
$59 — —
NEXLETOL
  • Esperion Therapeutics, Inc. $31
$31 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $30
$30 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

357 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record